Table 2. Adverse events reported in study eyes in ⩾5% of subjects (year 3, safety population) (n (%)).

Adverse event	All subjects who received active therapy for 3 years n = 161
Punctate keratitis	41 (25)
Intraocular pressure increased	32 (20)
Eye pain	27 (17)
Cataract	23 (14)
Vitreous floaters	18 (11)
Conjunctival haemorrhage	15 (9)
Anterior chamber inflammation	14 (9)
Corneal oedema	13 (8)
Vitreous opacities	13 (8)
Visual acuity reduced	10 (6)
Eye pruritus	8 (5)
Lacrimation increased	8 (5)